Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 6, 2015

View Archived Issues

OMEICOS' novel approach to treat atrial fibrillation receives BMBF research grant

Astellas Pharma presents milestones of second quarter of fiscal 2015

AADi initiates phase II trial of ABI-009 in PEComa

OticPharma licenses rights to Otodyne's otitis media program

International Stem Cell Corporation moves forward with PD trials in Australia

Osiris Therapeutics confirms addition to its wound care portfolio

Daiichi Sankyo offers overview of second quarter of fiscal 2015

Boehringer Ingelheim and BioMed X form psychiatric disease collaboration

AbbVie reports highlights of third quarter 2015

Novo Nordisk and University of Washington to investigate the brain's role in diabetes and obesity

Enumeral Biomedical reports progress in its anti-PD-1 antibody program

Phase I findings for Bavarian Nordic's MVA-BN Brachyury cancer vaccine

Volanesorsen lowers triglycerides in patients with familial chylomicronemia syndrome

Gene silencing oligonucleotides target microRNAs to treat atherosclerosis

Viking Therapeutics begins trial of VK-5211 in patients recovering from hip fracture

Recent collaborations to find or advance cancer therapeutics

Conjugation with guanidinoglycosides allow intranasal protein delivery for CNS targeting

Takeda Pharmaceutical discloses CDK8/19 inhibitors

Glenmark Pharmaceuticals patents ROR-gamma modulators

Chengdu University divulges irreversible glyoxalase I inhibitors

Roche presents TLR7/8 agonists

University of Michigan reports Mdm2 inhibitors

ArmaGen receives rare pediatric disease designation from FDA for AGT-181

Priority review status for AstraZeneca's AZD-9291 granted by MHLW in Japan

AstraZeneca to acquire ZS Pharma

FDA approves Genvoya single-tablet regimen for HIV-1

Calcipotriol formulation has promising effects in patients with nail psoriasis

New Alzheimer's disease model links beta-amyloid amyloidosis and tau pathology

Blood test predicts effect of nivolumab on survival in patients with melanoma

Axovant acquires nelotanserin, expands development of RVT-101

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 4, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...